IL1B and obesity disorder: Studies suggested that diet can affect inflammation and may produce clinically relevant endpoints in the form of increasing AHR, blocking IL-1β signaling with the IL-1 receptor antagonist anakinra, and reducing ILC3 and AHR in a mouse model of obesity (Kim et al., 2014).